Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Atazanavir
100%
Treatment Interruption
100%
Antiretroviral Therapy
53%
Resistance mutations
30%
Proteasome Inhibitor Resistance
30%
Reinitiation
30%
Protease Inhibitors
23%
HIV RNA
23%
Resistance Evaluation
23%
Odds Ratio
15%
95% Confidence Interval
15%
New mutation
7%
Logistic Regression
7%
Non-adherence
7%
Nave
7%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
7%
Nucleoside Reverse Transcriptase Inhibitors
7%
Virological Failure
7%
CD4 Count
7%
Methadone
7%
Current Guidelines
7%
Antiretroviral Therapy Regimens
7%
Virological Response
7%
Lopinavir
7%
Genetic Resistance
7%
Injecting Drug Users
7%
Interruption Duration
7%
Drug Intolerance
7%
RNA Copies
7%
Ritonavir-boosted Protease Inhibitors
7%
Minor mutation
7%
HIV-infected Patients
7%
Retrospective Evaluation
7%
Patient Median
7%
Medicine and Dentistry
Treatment Interruption
100%
Atazanavir
100%
Proteinase Inhibitor
61%
Antiretroviral Therapy
61%
Human Immunodeficiency Virus
30%
Resistance Mutation
30%
Ritonavir
15%
Odds Ratio
15%
Prevalence
7%
Logistic Regression Analysis
7%
Methadone
7%
Drug Intolerance
7%
Nonnucleoside Reverse Transcriptase Inhibitor
7%
Reverse-Transcriptase Inhibitor
7%
Injecting Drug User
7%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinase Inhibitor
100%
Atazanavir
100%
HIV
50%
Ritonavir
25%
Prevalence
12%
Nonnucleoside Reverse Transcriptase Inhibitor
12%
RNA Directed DNA Polymerase Inhibitor
12%
Methadone
12%
Drug Intolerance
12%
Biochemistry, Genetics and Molecular Biology
Treatment Interruption
100%
Protease Inhibitor
61%
RNA
23%
Human Immunodeficiency Virus
23%
Reverse Transcriptase
15%
Ritonavir
15%
Nucleoside
7%
Prevalence
7%
Human Immunodeficiency Virus 1
7%
CD4 Lymphocyte Count
7%
Methadone
7%